Non-prescription sleep aids

References 

  1. Attard KP, Adams RJT, Vakulin A, et al. Sleep and help seeking behaviours in Australia: a narrative review. OBM Neurobiology 2019;3(2):29. 
  2. O’Sullivan TA, Sy E, Bacci JL. Essential attributes for the community pharmacist as care provider. Am J Pharm Educ 2020;84(1):7125.
  3. Ashkanani FZ, Lindsey L, Rathbone AP. A systematic review and thematic synthesis exploring the role of pharmacists in supporting better sleep health and managing sleep disorders. Int J Pharm Pract 2023;31(2):153–64.
  4. Sansom L, ed. Insomnia. Australian pharmaceutical formulary and handbook; [updated Feb 16 2024]. At: https://apf.psa.org.au/treatment-guidelines-pharmacists/insomnia.
  5. Zhao FY, Xu P, Kennedy GA, et al. Identifying complementary and alternative medicine recommendations for insomnia treatment and care: a systematic review and critical assessment of comprehensive clinical practice guidelines. Front Public Health 2023;11:1157419.
  6. Sansom L, ed. Complementary medicines. Australian pharmaceutical formulary and handbook; [updated Feb 16 2024]. At: https://apf.psa.org.au/complementary-medicines/complementary-medicines.
  7. Baek JH, Nierenberg AA, Kinrys G. Clinical applications of herbal medicines for anxiety and insomnia; targeting patients with bipolar disorder. Aust N Z J Psychiatry 2014;48(8):705–15.
  8. Riemann D, Espie CA, Altena E, et al. The European insomnia guideline: An update on the diagnosis and treatment of insomnia 2023. Journal of Sleep Research 2023;32(6):e14035.
  9. Sateia Michael J, Buysse Daniel J, Krystal Andrew D, et al. Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: An American academy of sleep medicine clinical practice guideline. J Clin Sleep Med;13(02):307–49.
  10. Wilson S, Anderson K, Baldwin D, et al. British association for psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders: an update. J Psychopharmacol 2019;33(8):923–47.
  11. Therapeutic Guidelines. 2024. At: www.tg.org.au
  12. GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ 2004;328(7454):1490.
  13. Boon H, Kachan N, Boecker A. Use of natural health products: How does being “natural” affect choice? Med Decis Making 2012;33(2):282–97.
  14. Morin CM, LeBlanc M, Daley M, et al. Epidemiology of insomnia: Prevalence, self-help treatments, consultations, and determinants of help-seeking behaviors. Sleep Medicine 2006;7(2):123–30.
  15. 15. Cheung JMY, Jarrin DC, Beaulieu-Bonneau S, et al. Patterns of concomitant prescription, over-the-counter and natural sleep aid use over a 12-month period: a population based study. Sleep 2021;44(11):zsab
  16. Cheung JM, Bartlett DJ, Armour CL, et al. People with insomnia: experiences with sedative hypnotics and risk perception. Health Expect 2016;19(4):935–47.
  17. Givler D, Givler A, Luther PM, et al. Chronic Administration of melatonin: Physiological and clinical considerations. Neurol Int 2023;15(1):518–33.
  18. Ashy N, Shroff K, Ashy N, et al. Evaluation of the potential drug interaction of melatonin and warfarin: a case series. Life Sciences Journal 2016;13(6):46–51.
  19. Wirtz PH, Spillmann M, Bärtschi C, et al. Oral melatonin reduces blood coagulation activity: a placebo-controlled study in healthy young men. J Pineal Res 2008;44(2):127–33.
  20. Neubauer DN, Flaherty KN. Nonprescription pharmacotherapies: alcohol, over-the-counter, and complementary and alternative medicines.  John Hopkins University: CRC Press; 2016.
  21. Rossi S, ed. Australian medicines handbook. 2024. At: https://amhonline.amh.net.au/
  22. 22. Richardson GS, Roehrs TA, Rosenthal L, et al. Tolerance to daytime sedative effects of H1 antihistamines. J Clin Psychopharmacol 2002;22(5):511–5.
  23. 23. Albert SM, Roth T, Toscani M, et al. Sleep health and appropriate use of OTC sleep aids in older adults-recommendations of a gerontological society of America workgroup. Gerontologist 2017;57(2):163–70.
  24. Ruiz ME. Risks of self-medication practices. Curr Drug Saf 2010;5(4):315–23.
  25. 25. Gupta R, Zalai D, Spence DW, et al. When insomnia is not just insomnia: the deeper correlates of disturbed sleep with reference to DSM-5. Asian J Psychiatr 2014;12:23–30.
  26. Harvey AG. Insomnia: symptom or diagnosis? Clin Psychol Rev 2001;21(7):1037–59.
  27. Chang JL, Goldberg AN, Alt JA, et al. International consensus statement on obstructive sleep apnea. International Forum of Allergy & Rhinology 2023;13(7):1061–482.
  28. 28. Manconi M, Garcia-Borreguero D, Schormair B, et al. Restless legs syndrome. Nat Rev Dis Primers 2021;7(1):80.
  29. Australian Journal of General Practice. Restless legs syndrome. 2023. At: www1.racgp.org.au/ajgp/2023/september/restless-legs-syndrome
  30. Fuller JM, Wong KK, Krass I, et al. Sleep disorders screening, sleep health awareness, and patient follow-up by community pharmacists in Australia. Patient Educ Couns 2011;83(3):325–35.
  31. Hersberger KE, Renggli VP, Nirkko AC, et al. Screening for sleep disorders in community pharmacies-evaluation of a campaign in Switzerland. J Clin Pharm Ther 2006;31(1):35–41.
  32. Popattia AS, Hattingh L, La Caze A. Improving pharmacy practice in relation to complementary medicines: a qualitative study evaluating the acceptability and feasibility of a new ethical framework in Australia. BMC Med Ethics 2021;22(1):3.